243 related articles for article (PubMed ID: 18671804)
1. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Marquard L; Gjerdrum LM; Christensen IJ; Jensen PB; Sehested M; Ralfkiaer E
Histopathology; 2008 Sep; 53(3):267-77. PubMed ID: 18671804
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Marquard L; Poulsen CB; Gjerdrum LM; de Nully Brown P; Christensen IJ; Jensen PB; Sehested M; Johansen P; Ralfkiaer E
Histopathology; 2009 May; 54(6):688-98. PubMed ID: 19438744
[TBL] [Abstract][Full Text] [Related]
3. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Suzuki J; Chen YY; Scott GK; Devries S; Chin K; Benz CC; Waldman FM; Hwang ES
Clin Cancer Res; 2009 May; 15(9):3163-71. PubMed ID: 19383825
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos.
Ma P; Schultz RM
Dev Biol; 2008 Jul; 319(1):110-20. PubMed ID: 18501342
[TBL] [Abstract][Full Text] [Related]
5. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
8. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
[TBL] [Abstract][Full Text] [Related]
9. Mutual Balance of Histone Deacetylases 1 and 2 and the Acetyl Reader ATAD2 Regulates the Level of Acetylation of Histone H4 on Nascent Chromatin of Human Cells.
Lazarchuk P; Hernandez-Villanueva J; Pavlova MN; Federation A; MacCoss M; Sidorova JM
Mol Cell Biol; 2020 Apr; 40(9):. PubMed ID: 32015101
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling.
Biçaku E; Marchion DC; Schmitt ML; Münster PN
Cancer Res; 2008 Mar; 68(5):1513-9. PubMed ID: 18316616
[TBL] [Abstract][Full Text] [Related]
11. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
12. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
13. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
14. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
15. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
17. HDAC2 deficiency and histone acetylation.
Ree AH; Folkvord S; Flatmark K
Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
[No Abstract] [Full Text] [Related]
18. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
19. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.
Hess L; Moos V; Lauber AA; Reiter W; Schuster M; Hartl N; Lackner D; Boenke T; Koren A; Guzzardo PM; Gundacker B; Riegler A; Vician P; Miccolo C; Leiter S; Chandrasekharan MB; Vcelkova T; Tanzer A; Jun JQ; Bradner J; Brosch G; Hartl M; Bock C; Bürckstümmer T; Kubicek S; Chiocca S; Bhaskara S; Seiser C
PLoS Genet; 2022 Aug; 18(8):e1010376. PubMed ID: 35994477
[TBL] [Abstract][Full Text] [Related]
20. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
Marchion DC; Bicaku E; Turner JG; Schmitt ML; Morelli DR; Munster PN
Mol Cancer Ther; 2009 Apr; 8(4):794-801. PubMed ID: 19372552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
